The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq’s opening bell in New York, marking the company’s awaited initial public offering. Founded in 2008 by ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the range it first proposed last week, in the vicinity of $400 million.

The IPO price was planned between the $19 and $20 range, up from the previous $16 and $18 planned price. The current pricing would value Caris Life Sciences at around $5.9 billion.

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here to find out why CAI stock is a Hold.

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million in a US initial public offering that priced above the top of its ...

Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the pricing of its initial public offering of ...

Caris Life Sciences Inc., a health care company that uses technology to help diagnose and treat cancer, raised $494 million in a U.S. initial public offering ...

In addition, Caris has granted the underwriters a 30-day option to purchase up to an additional 3,529,411 shares of common stock at the initial public offering price, less underwriting discounts ...

Caris Life Sciences shares rose on their first day of trading in their debut on Nasdaq. The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO ...

Cancer-testing company Caris Life Sciences surged in its stock-market debut Wednesday, continuing a run of strong initial public offerings for revenue-making healthcare companies.

IRVING, Texas, June 17, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the ...